Form 4: Paragon 28 Director Stephen Oesterle Reports Disposition of Shares and Options Following Merger with Zimmer Biomet
SEC Form 4 Filing
Stephen Oesterle, a director of Paragon 28, reports the disposition of common stock and stock options due to the merger with Zimmer Biomet Holdings, Inc.
Summary
- Stephen Oesterle, a director of Paragon 28, filed a Form 4 detailing changes in beneficial ownership.
- The filing is triggered by the merger between Paragon 28 and Zimmer Biomet Holdings, Inc., which became effective on April 21, 2025.
- As a result of the merger, Oesterle's holdings of Paragon 28 common stock and stock options were affected.
- Each share of common stock was converted into the right to receive $13.00 in cash and one contingent value right (CVR) potentially worth up to $1.00.
- Oesterle's stock options vested and were canceled, with Oesterle entitled to receive cash and CVRs based on the option's exercise price relative to the merger consideration.
- Specifically, 40,216 shares of common stock were disposed of.
- Additionally, options for 250,000 shares were disposed of.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it primarily reports factual information about the completion of a merger and the resulting changes in stock ownership. There are no explicit positive or negative implications for the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements beyond the completion of the merger.
Industry Context
This announcement reflects ongoing consolidation within the medical device industry, where larger companies like Zimmer Biomet acquire smaller, specialized firms like Paragon 28 to expand their product portfolios and market reach.
Stakeholder Impact
- Shareholders received $13.00 in cash and a CVR for each share.
- Option holders received cash or CVRs based on the terms of their options.
- The company is now a wholly owned subsidiary of Zimmer Biomet Holdings, Inc.
Key Dates
| Date | Description |
|---|---|
| January 28, 2025 | Date of the Agreement and Plan of Merger between Paragon 28, Zimmer Biomet Holdings, Inc., and Gazelle Merger Sub I, Inc. |
| April 21, 2025 | Effective date of the merger; date of transaction reported on Form 4. |
Keywords
Form 4, Merger, Paragon 28, Zimmer Biomet, Beneficial Ownership, Disposition, Stock Options, CVR
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.